A Study Of PF-03732010 In Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

February 28, 2011

Study Completion Date

February 28, 2011

Conditions
Neoplasms
Interventions
DRUG

PF-03732010

IV infusion. Escalating dose levels, starting at 0.5 mg/kg to Maximum Tolerated Dose. Cycle length of 4 weeks for first cycle, and 2 weekly for subsequently cycles was originally explored, yet based on emerging PK data the Cycle 1 duration is 2 weeks and then weekly. Number of Cycles: Until Progression or unacceptable toxicity develops.

Trial Locations (3)

3050

Pfizer Investigational Site, Parkville

19111

Pfizer Investigational Site, Philadelphia

110-744

Pfizer Investigational Site, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY